Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

Download PDF Copy

Apr 16 2010

NewsGuard 100/100 Score

Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets. Watson intends to begin shipping the product next week.

Toprol XL® 100 and 200 mg and its generic equivalents had total U.S. sales of approximately $403 million for the twelve months ending February 2010, according to IMS Health. Metoprolol succinate extended-release is a beta-blocker used to treat angina, heart failure and high blood pressure.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Tags: Acupuncture, Angina, Beta Blocker, Blood, Blood Pressure, Cancer, Cardiology, Food, Heart, Heart Failure, High Blood Pressure, Medicaid, Medicare, New Drug Application, Pharmaceuticals, Spine, Urology

Comments (0)

Download PDF Copy

Suggested Reading

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

SU2C announces grants to support cutting-edge research in a variety of cancers

SU2C announces grants to support cutting-edge research in a variety of cancers

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients